Blog

ANI Pharmaceuticals ANIP is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by

ANI Pharmaceuticals ANIP has shifted into a specialty-led growth story, with Cortrophin Gel now the main engine and the retina franchise positioned for a reset and recovery. At the same time, the

ANI Pharmaceuticals ANIP is setting up 2026 as a year where specialty medicines carry more of the weight. Management expects Rare Disease to represent about 60% of 2026 sales, signaling a continued

Acuity Brands, Inc. AYI is scheduled to announce second-quarter fiscal 2026 results on April 2, before the opening bell.In the last reported quarter, the company’s adjusted earnings and revenues

Ultragenyx Pharmaceutical RARE announced that the FDA has accepted its investigational new drug (IND) application for UX016, an investigational small-molecule prodrug of sialic acid, which is being

TransUnion TRU is benefiting from the rapid growth of the big data and analytics market. Its distinctive and comprehensive datasets, next-generation technology and its analytics and decision-making

Sanofi SNY announced that the European Commission has granted a conditional marketing authorization to Rezurock (belumosudil) for treating chronic graft-versus-host disease (GVHD) in adults and in

FactSet FDS has reported impressive results for second-quarter fiscal 2026, wherein both earnings and revenues surpassed the Zacks Consensus Estimate.

FDS’ earnings per share of $4.46 beat the

Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved its biosimilar to Amgen’s AMGN blockbuster drug, Prolia (denosumab). The biosimilar will be available in the United

Energy Fuels Inc. UUUU has taken a major step toward strengthening Western rare earth supply chains by successfully producing its first kilogram of high-purity terbium (Tb) oxide at its White Mesa

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Microsoft

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Pathward

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? KLA (KLAC), which belongs to the Zacks

Hims & Hers Health, Inc. HIMS is building a consumer-first digital healthcare platform that integrates diagnosis, treatment and fulfillment into a seamless, technology-enabled experience. Its model

Marvell Company Overview

Zacks Rank #3 (Hold) stock Marvell Technology (MRVL) is a fabless designer, developer, and marketer of analog, mixed-signal, and digital signal processing integrated

Citizens Financial Group, Inc.’s CFG shares have rallied 41.5% in the past year, outperforming the industry’s 19% rise. Further, CFG’s price performance has been better than that of its peers, Bank

JPMorgan Chase & Co. JPM has entered into a deal with Mitsubishi Corporation MSBHF. Per the agreement, Mitsubishi will use JPMorgan’s blockchain platform, Kinexys, to manage payments across its

United States Commodity ETF USCI is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has moved up 50.08% from its 52-week low price of $64.26 per share.

Are

Shares of United Therapeutics UTHR rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 study evaluating nebulized Tyvaso for the treatment of patients with

Netflix’s NFLX content strength remains the primary engine driving user engagement and revenue growth. The company is seeing strong traction from originals, with branded content viewing rising 9%

Tilray Brands, Inc. TLRY is expected to report third-quarter fiscal 2026 results on April 1, 2026, before the opening bell.The Zacks Consensus Estimate for revenues is pegged at $205.9 million

Investors might want to bet on BP (BP), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock

Investors might want to bet on Euroseas Ltd. (ESEA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one

Sera Prognostics, Inc. (SERA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even